Key Clinical Point: Black children with poorly controlled asthma had a superior response to stepped increases in inhaled glucocorticoids, compared with stepped increases in long-acting beta2-agonists.
Major finding: A total of 46% of black children with poorly controlled asthma improved when inhaled glucocorticoids were increased.
Study details: The data come from the BARD trials, a pair of prospective, randomized, double-blind trials including 280 children aged 5-11 years with at least one grandparent identified as black and 294 adolescents and adults who had family backgrounds that were similar to the children.
Disclosures: The study was supported by the National Heart, Lung, and Blood Institute. Dr. Wechsler reported relationships with companies including AstraZeneca, Equillium, Genentech, GlaxoSmithKline, Mylan, Novartis, Regeneron, resTORbio, Sanofi, and others. Coauthors identified relationships with numerous pharmaceutical companies.
Wechsler ME et al. N Engl J Med. 2019 Sep 25. doi: 10.1056/NEJMoa1905560